奧昔非君

化合物

奧昔非君INN:oxyfedrine)是一種血管擴張劑[1]β腎上腺素受體激動劑[2][3]

奧昔非君
臨床資料
AHFS/Drugs.com國際藥品名稱
ATC碼
識別資訊
  • (RS)-3-[(2-Hydroxy-1-methyl-2-phenylethyl)amino]-1-(3-methoxyphenyl)propan-1-one
CAS號15687-41-9  checkY
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
化學資訊
化學式C19H23NO3
摩爾質量313.40 g·mol−1
3D模型(JSmol英語JSmol
  • C[C@@H]([C@@H](c1ccccc1)O)NCCC(=O)c2cccc(c2)OC
  • InChI=1S/C19H23NO3/c1-14(19(22)15-7-4-3-5-8-15)20-12-11-18(21)16-9-6-10-17(13-16)23-2/h3-10,13-14,19-20,22H,11-12H2,1-2H3/t14-,19-/m0/s1
  • Key:GDYUVHBMFVMBAF-LIRRHRJNSA-N

研究發現,它可以抑制冠狀血管的張力,[4]改善心肌代謝(使心臟更好地撐過缺氧),並發揮正變時英語Chronotropic正性肌力英語Inotrope作用,從而避免誘發心絞痛[4][5]正性變時性和正性肌力作用尤其重要,因為用於心絞痛的其他血管擴張劑可能會適得其反,導致冠狀動脈竊血英語Coronary steal現象。[6]

有研究提出奧昔非君可與抗生素產生協同作用。[7]

合成

 
專利:[8]

參考資料

  1. ^ Otsuki, Yuji; Yamasaki, Juntaro; Suina, Kentaro; Okazaki, Shogo; Koike, Naoyoshi; Saya, Hideyuki; Nagano, Osamu. Vasodilator oxyfedrine inhibits aldehyde metabolism and thereby sensitizes cancer cells to xCT-targeted therapy. Cancer Science. 2020-01, 111 (1) [2024-05-09]. ISSN 1349-7006. PMC 6942438 . PMID 31692172. doi:10.1111/cas.14224. (原始內容存檔於2024-05-09). 
  2. ^ Sakai, Kazushige; Shiraki, Yasuyuki; Hashimoto, Koroku. An analysis of the ß-adrenergic action of oxyfedrine. European Journal of Pharmacology. 1973-01-01, 21 (1). ISSN 0014-2999. doi:10.1016/0014-2999(73)90210-0. 
  3. ^ Beckett, P. R.; Foster, R. W. Oxyfedrine — A partial agonist at β-adrenoceptors. European Journal of Pharmacology. 1972-11-01, 20 (2). ISSN 0014-2999. doi:10.1016/0014-2999(72)90145-8. 
  4. ^ 4.0 4.1 Chichkanov, G. G.; Chumburidze, V. B. [Mechanism of the antianginal action of oxyfedrine]. Farmakologiia I Toksikologiia. 1977, 40 (3) [2024-05-09]. ISSN 0014-8318. PMID 20326. (原始內容存檔於2024-06-14). 
  5. ^ Jc, Kaski; L, Araujo; A, Maseri. Effects of oxyfedrine on regional myocardial blood flow in patients with coronary artery disease. Cardiovascular drugs and therapy. 1991 Dec, 5 (6) [2024-05-09]. ISSN 0920-3206. PMID 1801897. doi:10.1007/BF00143526. (原始內容存檔於2024-05-09) (英語). 
  6. ^ Chichkanov, G. G.; Bogolepov, A. K.; Matsievskiĭ, D. D. [Mechanism of the effect of anti-angina drugs with adrenergic beta receptor agonist action on the collateral hemodynamics and redistribution of the blood flow in chronic myocardial ischemia]. Kardiologiia. 1981-10, 21 (10). ISSN 0022-9040. PMID 6117671. 
  7. ^ Mazumdar K, Dutta NK, Kumar KA, Dastidar SG. In vitro and in vivo synergism between tetracycline and the cardiovascular agent oxyfedrine HCl against common bacterial strains. Biological & Pharmaceutical Bulletin. April 2005, 28 (4): 713–7 [2024-05-09]. PMID 15802815. doi:10.1248/bpb.28.713 . (原始內容存檔於2024-06-06). 
  8. ^ Thiele Kurt, 美國專利第3,225,095號 (1965 to Degussa).